Maramag C, Menon M, Balaji K C, Reddy P G, Laxmanan S
Division of Urologic and Transplantation Surgery, University of Massachusetts Medical Center, Worcester 01655, USA.
Prostate. 1997 Aug 1;32(3):188-95. doi: 10.1002/(sici)1097-0045(19970801)32:3<188::aid-pros5>3.0.co;2-h.
Many studies describe the protective role of vitamin C (ascorbic acid) against cancer development and in treatment of established cancer. The present study investigated whether ascorbic acid demonstrates a therapeutic benefit for prostate cancer.
Androgen-independent (DU145) and androgen-dependent (LNCaP) human prostate cancer cell lines were both treated in vitro with vitamin C (0-10 mM). Cell counts, cell viability, and thymidine incorporation into DNA were determined.
Treatment of DU145 and LNCaP cells with vitamin C resulted in a dose- and time-dependent decrease in cell viability and thymidine incorporation into DNA. Vitamin C induced these changes through the production of hydrogen peroxide; addition of catalase (100-300 units/ml), an enzyme that degrades hydrogen peroxide, inhibited the effects of ascorbic acid. Superoxide dismutase, an enzyme that dismutates superoxide and generates hydrogen peroxide, did not prevent decreases in cell number and DNA synthesis, suggesting further the involvement of hydrogen peroxide in vitamin C-induced changes. These results clearly indicate that reactive oxygen species (ROS) are involved in vitamin C-induced cell damage. However, that singlet oxygen scavengers such as sodium azide and hydroquinone and hydroxyl radical scavengers such as D-mannitol and DL-alpha-tocopherol did not counteract the effects of ascorbic acid on thymidine incorporation suggests that vitamin C-induced changes do not occur through the generation of these ROS.
Vitamin C inhibits cell division and growth through production of hydrogen peroxide, which damages the cells probably through an as yet unidentified free radical(s) generation/mechanism. Our results also suggest that ascorbic acid is a potent anticancer agent for prostate cancer cells.
许多研究描述了维生素C(抗坏血酸)在预防癌症发生及治疗已确诊癌症方面的保护作用。本研究调查了抗坏血酸对前列腺癌是否具有治疗益处。
用维生素C(0 - 10 mM)体外处理雄激素非依赖性(DU145)和雄激素依赖性(LNCaP)人前列腺癌细胞系。测定细胞计数、细胞活力以及胸苷掺入DNA的情况。
用维生素C处理DU145和LNCaP细胞导致细胞活力及胸苷掺入DNA呈剂量和时间依赖性下降。维生素C通过产生过氧化氢诱导这些变化;添加过氧化氢酶(100 - 300单位/毫升),一种降解过氧化氢的酶,可抑制抗坏血酸的作用。超氧化物歧化酶,一种使超氧化物歧化并产生过氧化氢的酶,不能阻止细胞数量和DNA合成的减少,这进一步表明过氧化氢参与了维生素C诱导的变化。这些结果清楚地表明活性氧(ROS)参与了维生素C诱导的细胞损伤。然而,诸如叠氮化钠和对苯二酚等单线态氧清除剂以及诸如D - 甘露醇和DL - α - 生育酚等羟基自由基清除剂不能抵消抗坏血酸对胸苷掺入的影响,这表明维生素C诱导的变化不是通过这些ROS的产生而发生的。
维生素C通过产生过氧化氢抑制细胞分裂和生长,过氧化氢可能通过一种尚未明确的自由基产生/机制损害细胞。我们的结果还表明抗坏血酸是一种对前列腺癌细胞有效的抗癌剂。